The VERTU trial is a phase 2 trial of VEliparib, Radiotherapy and Temozolomide trial in Unmethylated MGMT Glioblastoma.

Tumour tissue from patients are tested at a central laboratory for MGMT gene methylation – only those patients who have an ‘unmethylated’ MGMT gene status are eligible for the trial.